DDInter192 DDInter927
A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Bepridil {u} (Compound) resembles {v} (Compound) Diphenidol
Bepridil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Bepridil {u} (Compound) resembles {v} (Compound) Fentanyl
Bepridil {u} (Compound) treats {v} (Disease) hypertension
Bepridil {u} (Compound) binds {v} (Gene) CACNA1D
Bepridil {u} (Compound) causes {v} (Side Effect) Insomnia
Bepridil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Bepridil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Bepridil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcium glubionate anhydrous
Bepridil {u} may lead to a major life threatening interaction when taken with {v} Eliglustat
Bepridil (Compound) resembles Diphenidol (Compound)
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Bepridil (Compound) resembles Fentanyl (Compound)
Bepridil (Compound) treats hypertension (Disease)
Bepridil (Compound) binds CACNA1D (Gene)
Bepridil (Compound) causes Insomnia (Side Effect)
Bepridil may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Bepridil may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Bepridil may lead to a major life threatening interaction when taken with Eliglustat